Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Anticancer Research · 2023
DOI: 10.21873/anticanres.16651 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Yujiro Nagata und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan yujiro-nagata@med.uoeh-u.ac.jp. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Phenylthiohydantoin, Prostate-Specific Antigen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan yujiro-nagata@med.uoeh-u.ac.jp.
- Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Zitieren
APA
Nagata, Y., Jojima, K., Matsukawa, T., Tomisaki, I., & Fujimoto, N. (2023). Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.16651
Vancouver
Nagata Y, Jojima K, Matsukawa T, Tomisaki I, Fujimoto N. Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer. Anticancer Research. 2023. doi:10.21873/anticanres.16651
BibTeX
@article{Nagata2023,
author = {Nagata, Yujiro and Jojima, Kazumasa and Matsukawa, Takuo and Tomisaki, Ikko and Fujimoto, Naohiro},
title = {Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16651}
}
EUVIMED